EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: A Multicentre Network Study

Giacomo Tini, Paolo Milani, Mattia Zampieri, Angelo G Caponetti, Francesca Fabris, Andrea Foli, Alessia Argirò, Carlotta Mazzoni, Christian Gagliardi, Simone Longhi, Giulia Saturi, Giuseppe Vergaro und 39 weitere

European Journal of Heart Failure · 01.06.2023 · 25 (6) · 845-853

DOI: 10.1002/ejhf.2823 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, online erschienen am 15.03.2023. Verfasst von Giacomo Tini und 50 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, IRCCS OSpedale Policlinico San Martino, Genova, Italy. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Heart Failure, Cardiomyopathies. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Epidemiology of wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) remains poorly defined. A better characterization of pathways leading to ATTRwt-CA diagnosis is of key importance, and potentially informative of disease course and prognosis. The aim of this study was to describe the characteristics of contemporary pathways leading to ATTRwt-CA diagnosis, and their potential association with survival. Methods and results This was a retrospective study of patients diagnosed with ATTRwt-CA at 17 Italian referral centres for CA. Patients were categorized into different ‘pathways’ according to the medical reason that triggered the diagnosis of ATTRwt-CA (hypertrophic cardiomyopathy [HCM] pathway, heart failure [HF] pathway, incidental imaging or incidental clinical pathway). Prognosis was investigated with all-cause mortality as endpoint. Overall, 1281 ATTRwt-CA patients were included in the study. The diagnostic pathway leading to ATTRwt-CA diagnosis was HCM in 7% of patients, HF in 51%, incidental imaging in 23%, incidental clinical in 19%. Patients in the HF pathway, as compared to the others, were older and had a greater prevalence of New York Heart Association (NYHA) class III–IV and chronic kidney disease. Survival was significantly worse in the HF versus other pathways, but similar among the three others. In multivariate model, older age at diagnosis, NYHA class III–IV and some comorbidities but not the HF pathway were independently associated with worse survival.

Conclusions

Half of contemporary ATTRwt-CA diagnoses occur in a HF setting. These patients had worse clinical profile and outcome than those diagnosed either due to suspected HCM or incidentally, although prognosis remained primarily related to age, NYHA functional class and comorbidities rather than the diagnostic pathway itself.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialHeart FailureCardiomyopathiesHumansPrealbuminRetrospective Studies

Stichwörter der Autor:innen

Cardiac amyloidosisEpidemiology of cardiac amyloidosisTafamidisWild-type transthyretin cardiac amyloidosis

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Cardiology Unit, IRCCS OSpedale Policlinico San Martino, Genova, Italy.
  • Cardiology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
  • Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
  • Tuscan Regional Amyloidosis Centre|, Careggi University Hospital, Florence, Italy.
  • Cardiology Unit, St. Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID-Profile: Marco Canepa

Förderung

  • Pfizer Foundation

Zitieren

APA

Tini, G., Milani, P., Zampieri, M., Caponetti, A. G., Fabris, F., Foli, A., Argirò, A., Mazzoni, C., Gagliardi, C., Longhi, S., Saturi, G., Vergaro, G., Aimo, A., Russo, D., Varrà, G. G., Serenelli, M., Fabbri, G., De Michieli, L., Palmiero, G., …, & Canepa, M. (2023). Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: A Multicentre Network Study. European Journal of Heart Failure, 25(6), 845-853. https://doi.org/10.1002/ejhf.2823

Vancouver

Tini G, Milani P, Zampieri M, Caponetti AG, Fabris F, Foli A, et al. Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: A Multicentre Network Study. European Journal of Heart Failure. 2023;25(6):845-853. doi:10.1002/ejhf.2823

BibTeX
@article{Tini2023,
  author = {Tini, Giacomo and Milani, Paolo and Zampieri, Mattia and Caponetti, Angelo G and Fabris, Francesca and Foli, Andrea and Argirò, Alessia and Mazzoni, Carlotta and Gagliardi, Christian and Longhi, Simone and Saturi, Giulia and Vergaro, Giuseppe and Aimo, Alberto and Russo, Domitilla and Varrà, Guerino G and Serenelli, Matteo and Fabbri, Gioele and De Michieli, Laura and Palmiero, Giuseppe and Ciliberti, Giuseppe and Carigi, Samuela and Sessarego, Eugenio and Mandoli, Giulia E and Ricci Lucchi, Giulia and Rella, Valeria and Monti, Enrico and Gardini, Elisa and Bartolotti, Michela and Crotti, Lia and Merli, Elisa and Mussinelli, Roberta and Vianello, Pier Filippo and Cameli, Matteo and Marzo, Francesca and Guerra, Federico and Limongelli, Giuseppe and Cipriani, Alberto and Perlini, Stefano and Obici, Laura and Perfetto, Federico and Autore, Camillo and Porto, Italo and Rapezzi, Claudio and Sinagra, Gianfranco and Merlo, Marco and Musumeci, Beatrice and Emdin, Michele and Biagini, Elena and Cappelli, Francesco and Palladini, Giovanni and Canepa, Marco},
  title = {Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: A Multicentre Network Study},
  journal = {European Journal of Heart Failure},
  year = {2023},
  volume = {25},
  number = {6},
  pages = {845--853},
  doi = {10.1002/ejhf.2823}
}
Kostenlos starten →